Treatment
Sintilimab clinical trials
We’re tracking 172 recruiting studies that include Sintilimab, each written for real people, not researchers, below.
Recruiting studies
- NCT07521852RecruitingPhase 2
New drug combination with immunotherapy for liver cancer
This trial tests a new drug called CVM-1118 combined with an immunotherapy drug (sintilimab) and a procedure called TACE (a catheter-based treatment that delivers medicine directly to tumors) in people with hepatocellular carcinoma (liver cancer) that cannot be cured by surgery. The goal is to see if this combination is effective and safe.
Fuzhou, FujianAges 18 years+ - NCT07518602RecruitingPhase 2
Chidamide, Sintilimab, and Bevacizumab for Advanced Neuroendocrine Cancer
This trial tests a combination of three drugs—chidamide (a protein regulator), sintilimab (an immune-boosting antibody), and bevacizumab (a growth-blocking antibody)—for patients with advanced neuroendocrine cancer that has spread or cannot be removed surgically and has progressed despite an initial treatment. The goal is to see if this combination can shrink tumors and help patients live longer.
Guangzhou, GuangdongAges 18–75 - NCT06584032RecruitingPhase 3
Fruquintinib and Sintilimab for advanced endometrial cancer
This trial tests a combination of two drugs – fruquintinib (a pill that targets blood vessels feeding tumors) and sintilimab (an immunotherapy that helps your immune system fight cancer) – for people with advanced endometrial cancer that has already been treated with platinum chemotherapy. The goal is to see if this combination can help control the cancer and improve survival.
Beijing, Beijing MunicipalityAges 18–75 - NCT06761027RecruitingPhase 1/Phase 2
Three-drug chemo plus targeted and immune therapy for advanced pancreatic cancer
This trial tests a combination of three chemotherapy drugs (mFOLFIRINOX) along with anlotinib (a targeted therapy) and sintilimab (an immunotherapy) for people with advanced pancreatic cancer who have not had prior treatment. The goal is to see if this combination can help shrink tumors or slow the disease.
Fuzhou, FujianAges 18–75 - NCT07492615RecruitingPhase 2
Sintilimab plus chemo vs. chemo alone for stomach cancer after surgery
This trial tests whether adding the immunotherapy drug Sintilimab to standard chemotherapy after surgery can help prevent stomach or gastroesophageal junction cancer from coming back. It's for people with high-risk or advanced stage cancer that has a specific genetic feature (dMMR or MSI-H).
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07490262RecruitingPhase 2/Phase 3
Immunotherapy combo for advanced liver cancer as first treatment
This trial tests a new combination of two immunotherapy drugs (IBI310 and sintilimab) as a first treatment for advanced liver cancer that cannot be removed by surgery. It aims to see if this combination is safe and works better than current options.
Hefei, AnhuiAges 18–75 - NCT06776757RecruitingPhase 1/Phase 2
Sintilimab plus cetuximab and chemo for first-line advanced colorectal cancer
This trial tests a combination of immunotherapy (sintilimab), a targeted therapy (cetuximab), and chemotherapy as a first treatment for advanced colorectal cancer that hasn't spread or come back after earlier treatment. It's for people whose tumors have certain genetic markers (RAS/BRAF wild-type) and show signs of immune activity (PD-L1 or CD8+ TILs).
Shenzhen, GuangdongAges 18–75 - NCT07474103Recruiting
Chemo, radiation, and immunotherapy for high-risk rectal cancer
This trial tests a treatment plan that combines chemotherapy, radiation, and an immunotherapy drug before surgery for people with high-risk locally advanced rectal cancer. The goal is to see if this approach can improve outcomes.
WuhanAges 18–75 - NCT07457281RecruitingPhase 1
A new drug combo for head and neck cancer before surgery
This trial tests two drugs, GV20-0251 and Sintilimab, given before surgery for head and neck cancer. The goal is to see if this combination can shrink tumors and make surgery more effective.
ChengduAges 18–70 - NCT07459296RecruitingPhase 3
Becotatug vedotin plus sintilimab for advanced nasopharyngeal cancer
This trial tests a combination of two drugs, becotatug vedotin and sintilimab, for patients with a type of nasopharyngeal cancer that has spread to nearby lymph nodes but not to distant organs. It aims to see if this treatment can help control the disease.
Nanning, GuangxiAges 18–70 - NCT06808412RecruitingPhase 2
Sintilimab plus bevacizumab for untreated rectal cancer
This trial tests two drugs—sintilimab (an immunotherapy) and bevacizumab (a targeted therapy)—for people with rectal cancer that hasn't been treated yet. It aims to see if this combination can shrink the tumor before surgery.
Xi'an, ShaanxiAges 18–75 - NCT06714708RecruitingPhase 2
Low-dose radiation with immunotherapy and chemo before surgery for lung cancer
This trial tests a combination of low-dose radiation, an immunotherapy drug called sintilimab, and standard chemotherapy before surgery for stage II–III non-small cell lung cancer (NSCLC). The goal is to see if this approach can shrink tumors and improve outcomes for patients who are candidates for surgery.
Hefei, AnhuiAges 18 years+ - NCT07410975RecruitingPhase 2
Immunotherapy and chemo before surgery for lung cancer
This trial tests combining two immunotherapy drugs (anti-CTLA-4 antibody and sintilimab) with chemotherapy before surgery for stage II-III non-small cell lung cancer. The goal is to see if this approach helps shrink tumors and improve outcomes.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07400302RecruitingPhase 2
Sintilimab plus chemo for resected mucosal melanoma
This trial tests if adding sintilimab (an immunotherapy) to chemotherapy after surgery can lower the chance of mucosal melanoma coming back. It is for people whose melanoma has been fully removed and whose tumor tests positive for PD-L1.
Changchun, JilinAges 18 years+ - NCT07398326RecruitingPhase 2
Drug combo for advanced colorectal cancer that hasn't spread to the liver
This trial tests a combination of two drugs (anlotinib and sintilimab) as a first treatment for people with advanced colorectal cancer that has spread to places other than the liver, who do not want chemotherapy. The goal is to see if this targeted therapy can help control the cancer.
ShanghaiAges 18 years+ - NCT06456515Recruiting
Regorafenib, sintilimab, and electroacupuncture for advanced colorectal cancer
This trial tests a combination of two drugs (regorafenib and sintilimab) plus electroacupuncture for people with advanced colorectal cancer that hasn't responded to standard treatments. The goal is to see if this triple therapy can help shrink tumors or slow the cancer's growth.
ChangzhouAges 18–75 - NCT07371611RecruitingPhase 3
Sintilimab plus chemo before and after surgery for advanced oral cancer
This trial tests whether adding an immunotherapy drug (sintilimab) to standard chemotherapy before and after surgery can improve outcomes for people with advanced oral squamous cell carcinoma. The treatment is given first to shrink the tumor, then again after surgery to help prevent recurrence.
Guangzhou, GuangdongAges 18–75 - NCT06494943RecruitingPhase 1/Phase 2
Study of IBI110 and Sintilimab with Chemo for Head and Neck Cancer
This trial tests a combination of two immunotherapy drugs (IBI110 and sintilimab) with chemotherapy before surgery for people with advanced head and neck cancer that can be removed surgically. The goal is to see if this approach helps shrink tumors and improve outcomes.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05098847RecruitingPhase 2
Freezing liver tumors plus anti-cancer drugs for spread cancer
This trial tests whether freezing (cryoablation) liver metastases works better when combined with immunotherapy (sintilimab) and a targeted pill (lenvatinib). It’s for people whose cancer has spread to the liver and has not responded to earlier treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05057052RecruitingPhase 2
Freezing liver tumors with immunotherapy and a pill drug
This Phase 2 trial tests whether freezing (cryoablation) plus sintilimab (an immune system medicine) and regorafenib (a pill) can shrink colorectal cancer that has spread to the liver. It is for people whose cancer has come back or progressed after at least two prior chemotherapy treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05010681RecruitingPhase 2
Lenvatinib plus immunotherapy after prior liver cancer treatment
This Phase 2 trial tests lenvatinib combined with the immunotherapy drug sintilimab in people with advanced liver cancer who got worse after prior PD-1/PD-L1 treatment. It aims to slow cancer growth and improve outcomes after immune therapy hasn’t worked.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06848569RecruitingPhase 2
Sintilimab plus chemotherapy for pediatric Hodgkin lymphoma
This trial tests a combination of the immunotherapy drug sintilimab with chemotherapy (AVD) for children and teens with newly diagnosed low- or intermediate-risk Hodgkin lymphoma. The goal is to see if adding sintilimab can improve outcomes while reducing side effects.
Guangzhou, GuangdongAges 1–18 - NCT07350850RecruitingPhase 2
Methotrexate plus immunotherapy combo for untreated PCNSL
This trial tests a new combination of drugs (methotrexate, rituximab, sintilimab, and pirtobrutinib) against standard therapy for people with newly diagnosed primary central nervous system lymphoma (PCNSL) that has not been treated before. It aims to see if the combo works better and has manageable side effects.
Xiamen, FujianAges 18 years+ - NCT07351487RecruitingPhase 2
Chemo plus immunotherapy and anti-angiogenic drug for TNBC before surgery
This trial tests whether adding sintilimab (an immunotherapy) and bevacizumab (a drug that blocks blood supply to tumors) to standard chemotherapy before surgery can improve outcomes for women with stage II or III triple-negative breast cancer. It may help your immune system fight the cancer more effectively.
HefeiAges 18–75
Common questions
- Are there clinical trials studying Sintilimab?
- Yes. Clin2 currently lists 172 recruiting studies that include Sintilimab, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Sintilimab trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Sintilimab an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Sintilimab or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.